Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2091]

ASCO 2022: Breast cancer highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard...

Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma ( Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands )

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper...

Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib ( Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain )

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal...

Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour ( Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer

Dr Etienne Brain - Institut Curie, Paris, France

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer ( Dr Etienne Brain - Institut Curie, Paris, France )

ASCO 2022: Latest developments in mHSPC and mCRPC

Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller

ASCO 2022: Latest developments in mHSPC and mCRPC ( Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller )

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair...

Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer ( Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York )

Advance Prostate Cancer Consensus Conference 2021: Report

Prof Silke Gillessen and Prof Aurelius Omlin

Advance Prostate Cancer Consensus Conference 2021: Report ( Prof Silke Gillessen and Prof Aurelius Omlin )

The adverse events atlas, towards a strategy to predict synergistic adverse...

Prof Bart Westerman - Amsterdam UMC, Amsterdam, Netherlands

The adverse events atlas, towards a strategy to predict synergistic adverse events of combination therapies ( Prof Bart Westerman - Amsterdam UMC, Amsterdam, Netherlands )

PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1...

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )

Immune gene signatures for predicting response to neoadjuvant...

Dr Marta Casarrubios - Hospital Universitario Puerta de Hierro-Majadahonda...

Immune gene signatures for predicting response to neoadjuvant chemoimmunotherapy in NSCLC ( Dr Marta Casarrubios - Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain )

Real-world increase in biomarker testing in lung cancer

Dr Virginia Calvo de Juan - Hospital Universitario Puerta de Hierro-Majadahonda...

Real-world increase in biomarker testing in lung cancer ( Dr Virginia Calvo de Juan - Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain )

More from ecancer